PET/CT is a cost-effective tool against cancer: synergy supersedes singularity

Barbara Malene Fischer¹, Barry A Siegel², Wolfgang A Weber³, Konrade von Bremen^{4

5}, Thomas Beyer⁶, Antonis Kalemis^{5

7}

Affiliations

¹ Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
² Division of Nuclear Medicine, Mallinckrodt Institute of Radiology and Alvin J. Siteman Cancer Center, Washington University School of Medicine, Saint Louis, MO, USA.
³ Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁴ SWAN Isotopen AG, c/o Inselspital, 3010, Bern, Switzerland.
⁵ European Industrial Association for Nuclear Medicine and Molecular Healthcare (AIPES eeig), Brussels, Belgium.
⁶ Center for Medical Physics and Biomedical Engineering, General Hospital Vienna, Medical University of Vienna, Waehringer Guertel 18-20/4 L, 1090, Vienna, Austria. thomas.beyer@meduniwien.ac.at.
⁷ Philips, Advanced Molecular Imaging, Guildford, GU2 8XG, UK.

Editorial

Barbara Malene Fischer et al. Eur J Nucl Med Mol Imaging. 2016 Sep.

. 2016 Sep;43(10):1749-52.

doi: 10.1007/s00259-016-3414-5. Epub 2016 May 13.

Barbara Malene Fischer¹, Barry A Siegel², Wolfgang A Weber³, Konrade von Bremen^{4

5}, Thomas Beyer⁶, Antonis Kalemis^{5

7}

¹ Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
² Division of Nuclear Medicine, Mallinckrodt Institute of Radiology and Alvin J. Siteman Cancer Center, Washington University School of Medicine, Saint Louis, MO, USA.
³ Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁴ SWAN Isotopen AG, c/o Inselspital, 3010, Bern, Switzerland.
⁵ European Industrial Association for Nuclear Medicine and Molecular Healthcare (AIPES eeig), Brussels, Belgium.
⁶ Center for Medical Physics and Biomedical Engineering, General Hospital Vienna, Medical University of Vienna, Waehringer Guertel 18-20/4 L, 1090, Vienna, Austria. thomas.beyer@meduniwien.ac.at.
⁷ Philips, Advanced Molecular Imaging, Guildford, GU2 8XG, UK.

No abstract available

References

1. Fischer BM, Olsen MW, Ley CD, Klausen TL, Mortensen J, Højgaard L, et al. How few cancer cells can be detected by positron emission tomography? A frequent question addressed by an in vitro study. Eur J Nucl Med Mol Imaging. 2006;33(6):697–702. doi: 10.1007/s00259-005-0038-6. - DOI - PubMed
1. Wahl RL, Quint LE, Cieslak RD, Aisen AM, Koeppe RA, Meyer CR. “Anatometabolic” tumor imaging: fusion of FDG PET with CT or MRI to localize foci of increased activity. J Nucl Med. 1993;34(7):1190–1197. - PubMed
1. Fischer B, Lassen U, Mortensen J, Larsen S, Loft A, Bertelsen A, et al. Preoperative staging of lung cancer with combined PET-CT. N Engl J Med. 2009;361(1):32–39. doi: 10.1056/NEJMoa0900043. - DOI - PubMed
1. Maziak DE, Darling GE, Inculet RI, Gulenchyn KY, Driedger AA, Ung YC, et al. Positron emission tomography in staging early lung cancer; a randomized trial. Ann Intern Med. 2009;151(4):221–228. doi: 10.7326/0003-4819-151-4-200908180-00132. - DOI - PubMed
1. Dinan MA, Curtis LH, Carpenter WR, Biddle AK, Abernethy AP, Patz EF, Jr, et al. Redistribution of health care costs after the adoption of positron emission tomography among Medicare beneficiaries with non-small-cell lung cancer, 1998–2005. J Thorac Oncol. 2014;9(4):512–518. doi: 10.1097/JTO.0000000000000102. - DOI - PubMed